Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp > Q&A with Sarah Re, May 9 2022 News Release
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by general360on Jun 01, 2022 5:57pm
260 Views
Post# 34724749

RE:Q&A with Sarah Re, May 9 2022 News Release

RE:Q&A with Sarah Re, May 9 2022 News Release

Thanks for posting GV!

that make my fcuking blood boil.  Massive difference between inpatient and outpatient.  Looks like a shytti trial design, AGAIN.

and of course, Univerity of rvx will present at a scientific forum.. at a DATE TBD.
Looks like a nice long CORAL trial.  

not abandoned, but without completion. What kinda bs double speak is that. 

FKUCING INCOMPETENT MANAGEMENT. 


im about to stroke out from anger. Guess I won't take me some rvx208, that won't help me. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities